在双动脉 (BICATOR) 中对大动脉扩张和膜化进展的阿托瓦斯塔丁影响:随机临床试验
Arturo Evangelista1,2,3, Laura Galian-Gay1,3, Andrea Guala2,3
1Servei de Cardiologia (A.E., L.G.-G., G.T.-T., A.R.-M., M.A.C., H.C.-C., I.F.-G., J.F.R.-P.), Hospital Universitari Vall d´Hebron, Barcelona, Spain.
Circulation
|May 28, 2024
概括
在双主动脉患者中,阿托瓦斯丁没有减缓主动脉的扩张或化. 在这项研究中,在3年内,阿托瓦斯和安慰剂组之间没有显著的差异.
科学领域:
- 心脏病学
- 医学研究
背景情况:
- 双动脉 (BAV) 与上升性大动脉扩张和大动脉退化有关.
- 追溯研究表明,他类药物可能对BAV患者有益.
研究的目的:
- 评估阿托瓦斯塔丁在降低大动脉直径增长的有效性.
- 确定阿托瓦斯塔丁是否会减缓大动脉结的进展.
主要方法:
- 一项随机临床试验,涉及220名BAV患者,接受阿托瓦斯塔丁或安慰剂治疗3年.
- 纳入标准:年龄≥18岁,不严重的门功能障碍/化,上升性大动脉直径≤50毫米.
- 计算机断层扫描和心声扫描评估了基线和3年的结果.
主要成果:
- 在阿托瓦斯塔丁组中,低密度脂蛋白胆固醇显著降低 (P< 0. 001).
- 在阿托瓦斯塔丁 (0. 65毫米) 和安慰剂 (0. 74毫米) 组之间,上升的大动脉直径没有显著差异 (P=0. 613).
- 大动脉结石分数的进展或门功能障碍在两组之间没有显著差异 (P=0. 167).
结论:
- 在BAV患者中,阿托瓦斯丁治疗没有有效地减少上升性大动脉扩张的进展.
- 在没有严重功能的BAV患者中,阿托瓦斯丁并没有减缓主动脉的化进展.
- 尽管降低了LDL,但阿托瓦斯塔丁在3年内对这些BAV并发症没有益处.
更多相关视频
04:30Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
3.4K
08:55Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification
Published on: November 20, 2017
9.8K
相关概念视频
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
490
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
490
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
